| scholarly article | Q13442814 |
| P2093 | author name string | Suzuki G | |
| Sawada S | |||
| Takaku F | |||
| Kawase Y | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | T cell activation | Q14863969 |
| P304 | page(s) | 1797-1803 | |
| P577 | publication date | 1987-09-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation | |
| P478 | volume | 139 |
| Q49395944 | A Low Concentration of Tacrolimus/Semifluorinated Alkane (SFA) Eyedrop Suppresses Intraocular Inflammation in Experimental Models of Uveitis. |
| Q36094936 | A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease. |
| Q36362044 | Anhydroretinol: a naturally occurring inhibitor of lymphocyte physiology |
| Q40640423 | Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1 |
| Q41713722 | Antigen presentation and HLA-DR expression by FK-506-treated human monocytes |
| Q41267286 | Aqueous humor and serum penetration of tacrolimus after topical and oral administration in rats: an absorption study |
| Q34625889 | Calcium mobilization is both required and sufficient for initiating chromatin decondensation during activation of peripheral T-cells |
| Q71695988 | Changes in the mononuclear cell subpopulations of rat cardiac transplant recipients administered FK506 for the treatment of ongoing rejection |
| Q42484010 | Characterization and pharmacological modulation of antigen‐induced peritonitis in actively sensitized mice |
| Q90095233 | Circulating S100A8/A9 is potentially a biomarker that could reflect the severity of experimental colitis in rats |
| Q41677539 | Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production |
| Q69737091 | Cyclosporin A and anti-Ia antibody cause a maturation defect of CD4+8- cells in organ-cultured fetal thymus |
| Q50083027 | Cyclosporine A Induces MicroRNAs Controlling Innate Immunity during Renal Bacterial Infection. |
| Q41987358 | Cyclosporine inhibits mouse cytomegalovirus infection via a cyclophilin-dependent pathway specifically in neural stem/progenitor cells |
| Q50769958 | Cytotoxic effects of FK506 on human renal proximal tubule cells in culture. |
| Q54056179 | Dose study of the immunosuppression of FK 506 in canine lung allo-transplantation |
| Q73033656 | Effect of a single injection of high-dose FK506 on lung transplantation in rats |
| Q71621319 | Effects of FK506 and cyclosporin A on proliferation, histamine release and phenotype of murine mast cells |
| Q43620760 | Effects of FK506 on rat thymus: time-course analysis by immunoperoxidase technique and flow cytofluorometry |
| Q67676290 | Effects of a new immunosuppressive agent, FK 506, on the efferent limb of the immune responses |
| Q54332021 | Effects of a novel immunosuppressive agent, FK506, on human B cell activation |
| Q34197184 | Effects of combined administration of FK 506 and the purine biosynthesis inhibitors mizoribine or mycophenolic acid on lymphocyte DNA synthesis and T cell activation molecule expression in human mixed lymphocyte cultures |
| Q37199196 | Effects of cyclosporin A and FK506 on Fc epsilon receptor type I-initiated increases in cytokine mRNA in mouse bone marrow-derived progenitor mast cells: resistance to FK506 is associated with a deficiency in FK506-binding protein FKBP12 |
| Q44491856 | Effects of immunomodulators on airways hyperresponsiveness to adenosine induced in actively sensitised Brown Norway rats by exposure to allergen |
| Q34240244 | Effects of rapamycin on cultured hepatocyte proliferation and gene expression |
| Q37362163 | Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells |
| Q35031343 | Engineering the ABA plant stress pathway for regulation of induced proximity |
| Q24304321 | Expression and characterization of human FKBP52, an immunophilin that associates with the 90-kDa heat shock protein and is a component of steroid receptor complexes |
| Q34257329 | FK 506 and autoimmune disease: perspective and prospects |
| Q34240587 | FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice |
| Q34257088 | FK 506 prevents spontaneous diabetes in the BB rat |
| Q27931207 | FK 506-binding protein proline rotamase is a target for the immunosuppressive agent FK 506 in Saccharomyces cerevisiae |
| Q34251607 | FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh |
| Q41807884 | FK506 and Cyclosporin A Enhance IL-6 Production in Monocytes: A single-Cell Assay |
| Q35042532 | FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells |
| Q44958303 | FK506, a novel immunosuppressive agent, induces antigen-specific immunotolerance in active Heymann's nephritis and in the autologous phase of Masugi nephritis |
| Q42123192 | FK506: a novel immunosuppressive agent. Characteristics of binding and uptake by human lymphocytes |
| Q34257082 | Functional differentiation of human cytotoxic T lymphocytes in the presence of FK 506 and CyA |
| Q36230333 | Heterogenous graft rejection pathways in class I major histocompatibility complex-disparate combinations and their differential susceptibility to immunomodulation induced by intravenous presensitization with relevant alloantigens |
| Q34275070 | Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. |
| Q67653967 | Immunosuppressive activity of FK-506 in rats: flow cytometric analysis of lymphocyte populations in blood, spleen and thymus during treatment and following drug withdrawal |
| Q32060938 | Immunosuppressive drugs in paediatric liver transplantation |
| Q36399620 | Impairment of early fracture healing by skeletal muscle trauma is restored by FK506. |
| Q67674601 | In vivo 31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK506 |
| Q73486513 | In vivo rapid reduction of alloantigen-activated CD8+ mature cytotoxic T cells by inhibitors of acidification of intracellular organelles, prodigiosin 25-C and concanamycin B |
| Q41998451 | In-vitro interaction of a novel immunosuppressant, FK 506, and antacids |
| Q44344610 | Inhibition by FK506 of established lesions of collagen-induced arthritis in rats |
| Q43923204 | Inhibition of T and B lymphocyte proliferation by rapamycin |
| Q44051970 | Inhibition of T-lymphocyte activation by the immunosuppressive drug FK-506. |
| Q28367610 | Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog |
| Q69117623 | Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506 |
| Q43468818 | Inhibition of programmed cell death by cyclosporin A; preferential blocking of cell death induced by signals via TCR/CD3 complex and its mode of action |
| Q36799909 | Interpreting tacrolimus concentrations during pregnancy and postpartum. |
| Q42840700 | Intravitreal anti-inflammatory treatment for uveitis |
| Q28565470 | Intravitreal injection of Tacrolimus (FK506) suppresses ongoing experimental autoimmune uveoretinitis in Rats |
| Q40289666 | Introduction of a Framework for Dynamic Knowledge Representation of the Control Structure of Transplant Immunology: Employing the Power of Abstraction with a Solid Organ Transplant Agent-Based Model |
| Q37224269 | KRAS mutation leads to decreased expression of regulator of calcineurin 2, resulting in tumor proliferation in colorectal cancer |
| Q34302082 | Kidney transplantation under FK 506 |
| Q71609022 | Kinetic analysis of molecular interconversion of immunosuppressant FK506 by high-performance liquid chromatography |
| Q71627747 | Limited effectiveness of FK506 administration for ongoing rejection in heterotopic rat heart transplantation |
| Q41981167 | Liver, kidney, and thoracic organ transplantation under FK 506. |
| Q38778422 | Management of High-risk Corneal Transplantation |
| Q28368266 | Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus type 1 (HIV-1): interference with early and late events in HIV-1 replication |
| Q36825355 | Neisseria meningitidis encodes an FK506-inhibitable rotamase |
| Q40785466 | New immunosuppressive agents for pediatric transplantation |
| Q34567766 | Nontraditional microbial bioactive metabolites |
| Q34249336 | Ocular allergy treatments |
| Q26771818 | Ocular itch associated with allergic conjunctivitis: latest evidence and clinical management |
| Q37439873 | Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients |
| Q36627635 | Platelet activating factor synthesis and metabolism in intestinal ischaemia-reperfusion injury |
| Q40356519 | Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients |
| Q34275901 | Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors |
| Q27934061 | Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein |
| Q34764048 | Staphylococcal enterotoxin B causes proliferation of sensory C-fibers and subsequent enhancement of neurogenic inflammation in rat skin |
| Q44666916 | Successful topical treatment of cutaneous sarcoidosis with tacrolimus |
| Q34298815 | Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy |
| Q38904800 | Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation |
| Q34612464 | Tacrolimus (FK506) suppresses TREM-1 expression at an early but not at a late stage in a murine model of fungal keratitis |
| Q36596448 | Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis |
| Q40385566 | Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation |
| Q36126516 | Tacrolimus: in patients with rheumatoid arthritis |
| Q24295283 | The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis |
| Q41238756 | The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes. |
| Q45060105 | The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents |
| Q64389895 | The effects of CP 17193, an immunosuppressive pyrazaloquinoline, on the development of spontaneous lupus disease in NZBW F1 hybrid mice |
| Q67541729 | The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE) |
| Q35588481 | The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine |
| Q28274108 | The history of cyclosporin A (Sandimmune) revisited: another point of view |
| Q37091570 | The immunophilin ligands cyclosporin A and FK506 suppress prostate cancer cell growth by androgen receptor-dependent and -independent mechanisms |
| Q38334131 | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1 |
| Q36231731 | The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin |
| Q58746884 | The long-term effect of tacrolimus on alkali burn-induced corneal neovascularization and inflammation surpasses that of anti-vascular endothelial growth factor |
| Q34346326 | The role of small molecules in musculoskeletal regeneration |
| Q39168929 | Therapeutic effect of 0.1% Tacrolimus Eye Ointment in Allergic Ocular Diseases |
| Q35226825 | Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis |
| Q84203367 | Topical loteprednol etabonate 0.5 % for treatment of vernal keratoconjunctivitis: efficacy and safety |
| Q33552277 | Topical pimecrolimus as a new optional treatment in cutaneous sarcoidosis of lichenoid type |
Search more.